Novo Nordisk to invest $158 million in insulin plant in Brazil
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
This Is What Whales Are Betting On Novo Nordisk
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Reuters3d
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Oct 1 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its production due to sea port ...
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much as 4.6% to a seven-month low on Friday after a JPMorgan Chase & Co. analyst ...
U.S. News & World Report3d
Novo Nordisk Has Mitigation Plans to Minimize Disruption From Port Strikes, CNBC Reports
(Reuters) - Danish drugmaker Novo Nordisk has mitigation plans in place to minimize or prevent any disruption to its production due to sea port strikes in the United States, CNBC reported on ...